Terminated PHASE2 INTERVENTIONAL NCT00469703

Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis

A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis.

Sponsor: Celgene Corporation

Conditions Chronic Pancreatitis

Interventions Thalidomide

Updated 5 times since 2017 Last updated: Jan 10, 2008 Started: Aug 31, 2005 Primary completion: Nov 30, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Other terminated trials from Celgene Corporation

More terminations from Celgene Corporation

Other Chronic Pancreatitis trials with similar outcome

Browse all Chronic Pancreatitis trials

Listed as NCT00469703, this PHASE2 trial focuses on Chronic Pancreatitis and remains terminated or withdrawn. Sponsored by Celgene Corporation, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Winthrop University Hospital

Data source: Winthrop University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.